SCHEMBL5048619

SCHEMBL5048619

COc1ccc(-c2nc(-c3cc(C(=O)NCC4CCCCC4)c(C)n3Cc3cccs3)cs2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
MAPT P10636 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
KLKB1 P03952 6/20 0.47
ESR1 P03372 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CDC25A P30304 2/20 0.42
CDC25B P30305 2/20 0.42
CDC25C P30307 2/20 0.42
DUSP3 P51452 2/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
CRHBP P24387 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5043921 0.91 KLKB1 (0.52) ALDH1A1MAPTKLKB1CDC25ACDC25B
SCHEMBL5039244 0.89 KLKB1 (0.46) ALDH1A1MAPTNPC1RAB9AKLKB1
SCHEMBL5044250 0.89 MAPT (0.52) ALDH1A1MAPTL3MBTL1NPC1RAB9A
SCHEMBL5047596 0.89 KLKB1 (0.49) ALDH1A1MAPTNPC1RAB9AKLKB1
SCHEMBL5044887 0.86 KLKB1 (0.47) ALDH1A1MAPTNPC1RAB9AKLKB1
SCHEMBL5039266 0.86 NPC1 (0.51) ALDH1A1MAPTL3MBTL1NPC1RAB9A
SCHEMBL5132199 0.86 MAPT (0.59) ALDH1A1MAPTNPC1RAB9AKLKB1
SCHEMBL5133778 0.86 ALDH1A1 (0.51) ALDH1A1MAPTNPC1RAB9AKLKB1
SCHEMBL5133244 0.85 KLKB1 (0.40) NPC1RAB9AKLKB1KLK1
SCHEMBL5046853 0.85 CDC25A (0.59) ALDH1A1MAPTL3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R ALDH1A1 959/4885MAPT 3334/4885L3MBTL1 4036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.